Compare Biogen Inc (BIIB) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Biogen Inc trades at $191.89 (market cap $28.34B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.62. The key difference: Biogen Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| BIIB | TMF | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $44.14 |
52-Week Low | $122.68 | $31.85 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
TMF, a leveraged ETF tracking long-term US Treasuries, trades at $32.81, down 1.83% today. Technical indicators are bearish overall, with moving averages signaling strong selling pressure, though oscillators show some bullish momentum. The stock lacks traditional fundamental metrics like P/E or revenue due to its ETF structure, relying instead on underlying bond performance and interest rate trends.
Outlook remains volatile, driven by Federal Reserve policy shifts and bond market fluctuations. Risks include daily leverage decay and interest rate sensitivity. Analyst sentiment is mixed, with some seeing opportunity at bond market lows, while others caution against long-term holds due to amplified losses in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
